# Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.

> **NCT06762431** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Vitebsk Regional Clinical Cancer Centre** · enrollment: 60 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukaemia (CLL)
- Small Lymphocytic Lymphoma (SLL)

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT06762431
- **Lead sponsor:** Vitebsk Regional Clinical Cancer Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-11-04
- **Primary completion:** 2026-03-09
- **Final completion:** 2026-08-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06762431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06762431, "Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06762431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*